Tag Archives: Dementia Research: UK Impact

Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)

Posted on May 2, 2016 by Dementia and Elderly Care News

Summary Additional partnership funding has been announced for Dementia Research Institute (DRI). The Alzheimer’s Society and Alzheimer’s Research UK have each committed £50 million towards supporting the work of the Institute, making the total commitment to date around £250 million … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Drug Discovery Alliance, ARUK: Alzheimer’s Research UK, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Cross-Sector Partnerships, David Cameron, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Institute (DRI), Dementia Research: UK Impact, Dementia Risk Reduction, Department for Business Innovation and Skills, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Alliance, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Dementia Discovery Fund (2015), Global Dementia Research, Global Leadership, Global Outlook, Hilary Evans: Chief Executive of Alzheimer’s Research UK, International Dementia Research, Jeremy Hughes CBE: Chief Executive of the Alzheimer’s Society, Jo Johnson MP, Jo Johnson: Universities and Science Minister, Living Well with Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, Partnership and Collaboration, Partnership Working, Prime Minister’s Challenge On Dementia 2020, Promisary Science, Public Health Strategies, Research and Development, Research and Innovation, Research Commitment, Research Funding, Sir John Savill: Chief Executive of the Medical Research Council, UK Dementia Research Institute | Leave a comment

Who and What is the Dementia Envoy? (WDC / Department of Health)

Posted on March 8, 2016 by Dementia and Elderly Care News

Summary The Prime Minister has appointed David Mayhew as the latest Dementia Envoy. Dennis Gillings was the former World Dementia Envoy. “The envoy works with countries, corporations and leaders from around the world, sharing expertise and promoting research and support … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Researchers (mostly), In the News, International, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Academia-Industry Partnerships, Alzheimer’s Research UK (ARUK), British Prime Minister's Office, Challenge on Dementia (David Cameron), Collaborative Projects, Cross-Sector Partnerships, Data Sharing, David Cameron, David Mayhew CBE: Former Chairman of JP Morgan Cazenove, David Mayhew CBE: Vice Chairman of JP Morgan’s Global Investment Bank, David Mayhew CBE: Wellcome Trust Investment Committee, David Mayhew: Chairman of Alzheimer’s Research UK, David Mayhew: Dementia Envoy (2016-), Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Friends, Dementia Innovation, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Envoy for Dementia Innovation, Global Outlook, Global Social Investment for Dementia, Government Research Funding, International Collaborations, International Programmes, JP Morgan, Knowledge Translation, Leadership, Partnership, Partnership and Collaboration, Partnership Working, Prime Minister's Challenge on Dementia, Prime Minister's Office, Prime Minister’s Dementia Challenge, Research and Innovation, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, WDC: World Dementia Council, World Alzheimer Report 2014, World Dementia Council, World Dementia Envoy | Leave a comment

Significant Changes at the World Dementia Council? (WDC)

Posted on February 28, 2016 by Dementia and Elderly Care News

Summary There has been reform within the World Dementia Council (WDC). The changes are intended to make this body “more representative” in global terms (if such were possible) and fully independent. The Council now includes a wider range of international … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, Diagnosis, For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, UK, Universal Interest, World Health Organization (WHO) | Tagged Abuse of Vulnerable Adults, Academia-Industry Partnerships, Academic Research, Alternatives to Antipsychotic Drugs, Alzheimer's Association, Alzheimer’s Disease: Risk Factors, Alzheimer’s Research UK (ARUK), Argentina, ARUK: Alzheimer’s Research UK, Assistive Technology, Associate Members (WDC), Awareness, Awareness Raising, Behavioural Risk Factors, Big Data, Big Data Partnership, Big Pharma, Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Biotechnology, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Friends, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dementia Risk Factors, Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, Department of Health’s Integrated Development Initiative, Digital Technology, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Yves Joanette: Scientific Director of Canadian Institute of Health Research (Institute of Aging), Emerging Technology, Enabling Technology, Future Long-Term Care Costs, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Outlook, Global Social Investment for Dementia, Government Research Funding, Hilary Doxford: World Dementia Council Member, Indonesia, Information Technology, Innovative Technology, International Collaborations, International Dementia Research Inventories, International Programmes, Interventions for Social Isolation and Loneliness in Men, Investment in Technology, Join Dementia Research, Leveraging Big Data, Lifestyle Risk Factors, Loneliness and Social Isolation, Modifiable Risk Factors, National Institute of Ageing (NIA), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, Nigeria, Open Data and Big Data, Organisation for Economic Co-operation and Development (OECD), Partnership and Collaboration, Partnership Working, Philanthropic Funding, Pipeline Databases, Prevention, Prevention of Dementia, Prime Minister’s Challenge On Dementia 2020, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Raj Long: Vice Chair of World Dementia Council, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Stigma, Regulatory Agencies, Regulatory Experts, Research and Development, Research and Innovation, Research Commitment, Research Funding, Resource and Incentives, Restraint and Restrictions, Restraint in Health and Adult Social Care, Risk Factors, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Social Isolation, Stigma, Taiwan, Treatment and Prevention of Dementia, US National Institute on Aging, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO), Yves Joanette: Chair of World Dementia Council | Leave a comment

Government Commitment to the Global Action Against Dementia (WDC / Department of Health)

Posted on November 25, 2015 by Dementia and Elderly Care News

Summary The Department of Health has responded to Raj Long’s Finding a path for a cure for dementia: an independent report into an integrated approach to dementia drug development report, with a Strategy Report and an open letter. There is … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest, World Health Organization (WHO) | Tagged $100m Dementia Discovery Fund, Academia-Industry Partnerships, Academic Research, Accelerated Access Review, AIFA: Italian Medicines Agency, Alzheimer's Association, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, Bill and Melinda Gates Foundation, Biopharmaceutical Companies, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP), Composite End Points, Continuity Plans (WDC and GAAD Agenda), Council for International Organizations of Medical Sciences (CIOMS), Cross-Sector Partnerships, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Integrated Development Initiative, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Department of Health Dementia Challenge, Department of Health’s Integrated Development Initiative, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, EMA: European Medicines Agency, EU Joint Programme on Neurodegenerative Disease Research (JPND), EU’s Neurodegenerative Disease Research Joint Programme (JPND), European Medicines Agency, European Medicines Agency (EMA), European Prevention of Alzheimer's Dementia Consortium (EPAD), First Global Ministerial Conference on Global Action Against Dementia, Foundation Plan Alzheimer’s, GAAD: Global Action Against Dementia, George Freeman MP: Former Life Sciences Minister, Gill Ayling: Deputy Director of Global Action Against Dementia (Department of Health), Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Alzheimer’s Leadership Series (GoALS), Global Alzheimer’s Platform, Global CEO initiative (CEOi) on Alzheimer’s Disease, Global Leadership, Global Ministerial Conference on Global Action Against Dementia (WHO), Global Observatory on Dementia (WHO), Global Outlook, Global Social Investment for Dementia, Government Research Funding, Integrated Development Advisory Group, International Coalition of Medicines Regulatory Agencies, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Pharmaceutical Regulatory Forum, International Programmes, Italian Medicines Agency, Jane Ellison MP: Parliamentary Under Secretary for Public Health, Joint Programme on Neurodegenerative Disease Research (JPND), JPND: Joint Programme on Neurodegenerative Disease Research, Medical Research Council (MRC), Modelling and Extrapolation, Multilateral Cooperation, National Institute for Health Research (NIHR), National Institute of Ageing (NIA), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, NeuroMap, New York Academy of Sciences (NYAS), Observatory on Dementia (WHO), OLS Accelerated Access Review, Organisation for Economic Co-operation and Development (OECD), Partnership and Collaboration, Partnership Working, Philanthropic Funding, Pipeline Databases, Prime Minister’s Challenge On Dementia 2020, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Regulatory Agencies, Regulatory Experts, Research and Development, Research and Innovation, Research Commitment, Research Funding, Resource and Incentives, Risk Benefit Balance, Swiss Medic, University of Newcastle, US National Institute on Aging, WDC: World Dementia Council, WHO Observatory on Dementia, WHO's Global Observatory on Dementia, World Dementia Council, World Health Organisation (WHO) | Leave a comment

Dementia: the R&D Landscape: Mapping UK Dementia Research and Workforce Capacity (RAND Europe / WDC / OHE)

Posted on October 27, 2015 by Dementia and Elderly Care News

Summary The Alzheimer’s Society commissioned RAND Europe to analyse the UK’s dementia research “landscape” and workforce capacity. The following report relates to the state of funding and capacity in dementia research. It covers: An audit of the types of research … Continue reading →

Challenges in Developing Disease-Modifying Treatments for Dementia (Department of Health)

Posted on July 23, 2015 by Dementia and Elderly Care News

Summary Raj Long, the Senior Regulatory Officer at the Bill & Melinda Gates Foundation, explores the problems in developing treatments for dementia. The independent “Finding a Path for the Cure for Dementia” report is a contribution to the G8 Dementia … Continue reading →

Posted in Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Academia-Industry Partnerships, Academic Research, AIFA: Italian Medicines Agency, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, BfArM: Federal Institute of Drugs and Medical Devices (Germany), Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Burden of Dementia, Canada, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Composite End Points, Consistent Global Development Pathways, Cross-Sector Partnerships, CTEG: Clinical and Technical Expert Group, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Denmark, Department of Health Dementia Challenge, Diagnosis and Referral, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, EMA: European Medicines Agency, European Medicines Agency, European Union, FIH: First in Humans, Financial Incentives, First Global Ministerial Conference on Global Action Against Dementia, Food and Drug Administration, G20 Countries, G7 Countries, G8 Dementia Summit: Global Action Against Dementia, G8 Summit, Gaps in the Basic Science, Germany, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Government Research Funding, Health Canada, IAP Steering Committee, IDAP Steering Committee, IDAP: International Dementia Advisory Platform, IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Incentives and Investment, Incentives for Drug Development, Independent Safety Review Committee, Integrated Development Pathway, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Programmes, Italian Medicines Agency, Italy, Japan, Japan: Pharmaceuticals and Medical Devices (Japan), Knowledge Translation, MEB: Medicines Evaluations Board, Medicines and Healthcare Products Regulatory Agency, Medicines Evaluation Board Netherlands, MHRA: Medicines and Healthcare Products Regulatory Agency, Modelling and Extrapolation, Multilateral Cooperation, Multilateral Regulator Cooperation, Netherlands, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, OHE: Office of Health Economics, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Science, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Organisation for Economic Cooperation and Development, Partnership, Partnership and Collaboration, Partnership Working, Patient Viewpoint, Philanthropic Funding, Pipeline Databases, PMDA: Pharmaceutical and Medicines Devices Agency, Public-Private Partnership (PPP), Quantifiable Reproducible Outcome Measures, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Reasons for Termination of Trials, Regulator Perspectives, Regulatory Agencies, Regulatory Experts, Research and Developers’ Status Quo, Research and Development, Research and Innovation, Research Commitment, Research Funding, Research Status Quo, Resource and Incentives, Risk Benefit Balance, Standardisation and Validation of Cognitive Endpoints, Swiss Medic, Switzerland, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO) | Leave a comment

Dementia 2015 UK Policy Report: Improving the Quality of Life for People with Dementia (Alzheimer’s Society)

Posted on July 7, 2015 by Dementia and Elderly Care News

Summary The Alzheimer’s Society’s fourth annual report exploring the quality of life for people with dementia (and their families and carers) in England, Wales and Northern Ireland, is entitled “Dementia 2015: Aiming higher to transform lives is in England”. This … Continue reading →

Posted in Acute Hospitals, Alzheimer's Society, Antipsychotics, Charitable Bodies, Commissioning, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Northern Ireland, Patient Care Pathway, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest, Wales | Tagged 2015 General Election Dementia Manifesto (All Party Parliamentary Group on Dementia), Active Lifestyle, Addressing Dementia: The OECD Response (2015), All Party Parliamentary Group on Dementia Manifesto for 2015 General Election, Alternatives to Antipsychotic Medication, Alzheimer's Society Policy Reports: Dementia 20xx Series, Alzheimer's Society: Dementia Friendly Communities Programme, Alzheimer’s Society Dementia Advisers, Alzheimer’s Society National Dementia Helpline, Alzheimer’s Society Public Policy Team, Alzheimer’s Society’s Carer Information and Support Programme (CrISP), Alzheimer’s Society’s Research Network, Alzheimer’s Society’s Supporting Diagnosis Project, APPG on Dementia, APPG on Dementia Manifesto 2015, Asda, Assessment of Quality of Life, Attributable Cost of Dementia, Aviva, Awareness and Understanding, Awareness Raising, Balancing Risk and Choice, Barbara Pointon’s Web of Care, Baroness Sally Greengross (APPG on Dementia), Barriers to Involvement, Barriers to Joined-Up Care, Barriers to Support, Barriers: Discrimination, Barriers: Lack of Continuity of Care, Barriers: Lack of Support for Carers, Blackfriars Consensus Statement, Burden of Dementia (Statistics), Care and Support, Care and Support Services, Care Homes, Caregiver Support, Carer Burden in Dementia, Carer Information and Support Programme, Carer Information and Support Programme (CrISP), Carer Support, Carers’ Health and Wellbeing, Central Lancashire’s Pathway of Post-Diagnostic Support Services, Challenge on Dementia 2020, Co-Morbidities and Dementia, Commissioners of Services, Commissioning Support Services, Community Support, Community Support Services, Cracks in the Pathway (CQC), Crawley Dementia Alliance, Dementia 2015 UK Policy Report, Dementia 2015: Aiming Higher to Transform Lives, Dementia Action Alliance (DAA), Dementia Adviser Service, Dementia Advisers, Dementia Advisor Service, Dementia Advisors, Dementia Awareness, Dementia Co-Morbidities, Dementia Diagnosis and Care in England, Dementia Diagnosis Rates, Dementia Friendly Communities Champion Group, Dementia Friendly Communities Programme, Dementia Friendly Swimming Project: Amateur Swimming Association (ASA), Dementia Friends, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dementia-Friendly Businesses, Dementia-Friendly Care Homes, Dementia-Friendly Cities, Dementia-Friendly Communities, Dementia-Friendly Health and Care Settings, Dementia-Friendly Hospitals, Dementia-Friendly Organisations, Dementia-Friendly Towns, Dementia-Friendly Workplaces, Deprivation of Liberty Safeguards (DoLS), Diagnosis and Referral, Disease-Modifying Therapies for Dementia, EasyJet, Focused Intervention Training and Support (FITS), Forget Me Not Dementia Unit (Warrington Hospital), G8 Summit, Global Alzheimer’s and Dementia Action Alliance (GADAA), Happiness and Wellbeing, Health and Quality of Life, Health and Social Care Reform, Health and Wellbeing, Health Care Support Received by People with Mental Health Problems, Health Commissioners, Health Wellbeing and Independence, Healthy Lifestyles, Home Retail Group (Argos and Homebase), Impact of Dementia (Statistics), Improving Dementia Education and Awareness, Improving the Quality of Life for People with Long Term Conditions, Inadequate Homecare Training, Increasing Wellbeing, Integrated Services in Tower Hamlets, Involvement and Participation, John's Campaign, Living Well with Dementia, Living Well with Dementia Research, Lloyds Banking Group, Loneliness and Social Isolation, Marks and Spencer, National Dementia Helpline, New Models of Care, NHS England’s Five Year Forward View, NHS England’s New Models of Care Programme, NHS Five Year Forward View (5YFV), Organisational and Cultural Barriers, Over-Complexity, Participation in Research, Patient Reported Outcome Measures (PROMs) in Dementia Study, Patient Reported Outcome Measures in Dementia, Post-Diagnosis Support, Post-Diagnostic Dementia Support, Prevalence of Dementia, Prime Minister’s Challenge On Dementia 2020, Public Health England, Quality of Care Across the Course of Dementia, Quality of Life, Quality of Life (Carers), Quality of Life for People With Dementia, Quality of Life Promotion, Quality of Life Research, Reducing Antipsychotic Prescriptions in Dementia, Reducing Complexity, Reducing Social Isolation: Side by Side, Right to Know Campaign, Risk Management, Risk Management Assessment, Risk Stratification, Social Isolation, St Gregory’s High School (Warrington), Support for New Models of Care (New Deal), Support Services, Supporting Healthy Lifestyles, Supporting People to Live Well With Dementia, Supreme Court Judgment (March 2015) on Deprivation of Liberty Safeguards (DoLS), Swimming With Dementia, Systems Complexity, Tower Hamlets, Web of Care, Workforce Development, Workforce Training, World Dementia Council | Leave a comment

UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)

Posted on February 16, 2015 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK has announced the launch of the Drug Discovery Alliance, a £30 million network of research centres working collaboratively on research to discover potential cures, or at least disease modifying treatments, for Alzheimer’s Disease and other forms … Continue reading →

Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)

Posted on December 22, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK has launched the Global Clinical Trials Fund (GCTF) to help finance trials which aim to translate discoveries in the lab into clinical treatments for the 830,000 people living with dementia in the UK. The GCTF aims … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, National, Non-Pharmacological Treatments, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest | Tagged Alzheimer’s Research UK Drug Discovery Institute, Clinical Research Networks, Clinical Trials, Clinical Trials (Phase I Through Phase III), Clinical Trials and Treatment Assessments, Collaboration, Collaborative Drug Discovery Programmes, Collaborative Projects, Commissioning Research, Dementia Consortium, Dementia Research, Dementia Research Priorities, Dementia Research: UK Impact, Disease Modifying Treatment by 2025 (Aim), Drug Discovery Institute, Drug Discovery Institutes, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Experimental Alzheimer's Drugs, First G8 Dementia Summit, G8 Dementia Summit, GCTF: Global Clinical Trials Fund, Global Action Against Dementia, Global Clinical Trials Fund (GCTF), International Collaborations, International Organisations, International Programmes, Intervention Trials, Medical Research, Multidisciplinary Research Teams, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, New Drug Applications (NDAs), Non-Drug Intervention Trials, Novel Targets in Neurodegeneration, Pharmaceutical Industry, Pharmacological Research, Pharmacological Treatments, Pharmacotherapy, Pre-Competitive Collaboration, Research Commitment, Research Consortia, Research Culture, Research Programmes, Technology Transfer, Translational Research | Leave a comment

Defeat Dementia Campaign (Alzheimer’s Research UK)

Posted on June 21, 2014 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK’s “Defeat Dementia” campaign was announced at the Global Dementia Legacy Event on June 19th 2014. Commitments included in the Defeat Dementia programme include: The launch of the Alzheimer’s Research UK Stem Cell Research Centre. There is a £2 … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Carers (mostly), For Researchers (mostly), In the News, Management of Condition, Quick Insights, UK, Universal Interest | Tagged Alzheimer’s Research UK Stem Cell Research Centre, Charitable Funding, Collaborative Projects, Cross-Sector Partnerships, Defeat Dementia Campaign, Defeat Dementia Campaign (Alzheimer’s Research UK), Dementia Challenge, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Research: UK Impact, Drug Discovery Institutes, G8 Dementia Summit, Genetic Research, Genetic Triggers, Global Action Against Dementia, Global Clinical Development Fund, Global Context, Global Dementia Legacy Event, Global Leadership, Global Outlook, Gurdon Institute: University of Cambridge, Innovation in Genetics, Knowledge Networks, Knowledge Translation, Networks, Networks and Alliances, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Philanthropic Funding, Philanthropy, Research Networks, Stem Cell Research, Stem Cell Research Centre, Translational Research, University College London, University of Cambridge | Leave a comment

Tag Archives: Dementia Research: UK Impact

Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)

UK-Based Drug Discovery Alliance (BBC News / Alzheimer’s Research UK)

Global Clinical Trials Fund: GCTF (Alzheimer’s Research UK)

Defeat Dementia Campaign (Alzheimer’s Research UK)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites